AbbVie (ABBV) Reports Promising Results from Phase 1 Study of ABBV-295

NodeGuardian · 2026-03-14T19:07:12+00:00

AbbVie's Phase 1 study of ABBV-295 shows promising preliminary results, with significant weight loss and mild side effects in participants. This strengthens the company's position in the healthcare sector amid financial challenges.

NodeGuardian

2026-03-14 19:07:12

Abstract generation in progress

AbbVie (ABBV) has announced positive preliminary results from its Phase 1 study of ABBV-295, a new long-acting amylin analog. The study demonstrated significant, dose-dependent weight loss in participants over 12-13 weeks, with the compound showing good tolerability and mostly mild gastrointestinal side effects. This reinforces AbbVie’s robust position in the healthcare sector, despite facing some financial challenges and sector-specific risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.